UNSPSC 51182101: Desmopressin

This classification denotes an antidiurectic hormone analogue with the molecular formula C46H64N14O12S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier ENR1LLB0FP, chemically known as vasopressin, 1-(3-mercaptopropanoic acid)-8-d-arginine- but generally known as desmopressin, which bears US NIH Compound Identifier 27991. European Medicines Agency schedules Desmopressin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07001MIG.

UNSPSC 51182101 Desmopressin is a Commodity code covering the supply of desmopressin and related pharmaceutical products to state and local government health care facilities, school districts, and correctional institutions. State and local governments procure desmopressin as part of broader pharmaceutical supply agreements with manufacturers and wholesalers, typically through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions to achieve volume pricing. The work involves product sourcing, regulatory compliance documentation, supply chain management through authorized pharmaceutical wholesalers, and pricing negotiation tied to National Drug Codes (NDC) and wholesale acquisition costs (WAC) or other standardized pricing methodologies. Issuing bodies include state departments of health and administration, state purchasing offices administering multistate cooperative agreements, and county and municipal health agencies that participate in group purchasing organizations (GPOs) or state cooperative purchasing alliances.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026, with a due date of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (75 percent of evaluation weight), compliance with Good Manufacturing Practices and the Drug Supply Chain Security Act, EDI capability, and flexible pricing formats including flat-price, net-price (NF30, NF60, NF90), and WAC-minus structures. Products must be marketplace-available by May 15, 2026, with awarded contracts effective July 1, 2026, and a two-year initial term with optional extensions.